CY1115504T1 - Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινη - Google Patents
Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινηInfo
- Publication number
- CY1115504T1 CY1115504T1 CY20141100686T CY141100686T CY1115504T1 CY 1115504 T1 CY1115504 T1 CY 1115504T1 CY 20141100686 T CY20141100686 T CY 20141100686T CY 141100686 T CY141100686 T CY 141100686T CY 1115504 T1 CY1115504 T1 CY 1115504T1
- Authority
- CY
- Cyprus
- Prior art keywords
- complexes
- platinum
- cisplatin
- phosphoplatin
- fas
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- BHKICZDKIIDMNR-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound N.N.[Pt+4].[O-]C(=O)C1(C([O-])=O)CCC1 BHKICZDKIIDMNR-UHFFFAOYSA-L 0.000 title 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
- 229960004316 cisplatin Drugs 0.000 abstract 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 3
- KTCQVFPGCRGZPS-UHFFFAOYSA-N P(=O)(=O)[Pt] Chemical compound P(=O)(=O)[Pt] KTCQVFPGCRGZPS-UHFFFAOYSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229960004562 carboplatin Drugs 0.000 abstract 2
- 190000008236 carboplatin Chemical compound 0.000 abstract 2
- 229910052697 platinum Inorganic materials 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- PVGAVTXIFQJKJI-UHFFFAOYSA-H platinum(2+);diphosphate Chemical compound [Pt+2].[Pt+2].[Pt+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O PVGAVTXIFQJKJI-UHFFFAOYSA-H 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95412607P | 2007-08-06 | 2007-08-06 | |
| US97392607P | 2007-09-20 | 2007-09-20 | |
| EP08797320.2A EP2173337B1 (en) | 2007-08-06 | 2008-08-06 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115504T1 true CY1115504T1 (el) | 2017-01-04 |
Family
ID=40342030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100686T CY1115504T1 (el) | 2007-08-06 | 2014-08-27 | Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινη |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7700649B2 (https=) |
| EP (2) | EP2668949A1 (https=) |
| JP (2) | JP5385274B2 (https=) |
| CN (1) | CN101801369B (https=) |
| CY (1) | CY1115504T1 (https=) |
| DK (1) | DK2173337T3 (https=) |
| ES (1) | ES2495743T3 (https=) |
| HR (1) | HRP20140808T1 (https=) |
| PL (1) | PL2173337T3 (https=) |
| PT (1) | PT2173337E (https=) |
| SI (1) | SI2173337T1 (https=) |
| WO (2) | WO2009021081A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2495743T3 (es) * | 2007-08-06 | 2014-09-17 | Ohio University | Fosfaplatinos y su uso en el tratamiento de cánceres resistentes a cisplatino y carboplatino |
| CN108210516A (zh) * | 2010-06-04 | 2018-06-29 | 俄亥俄大学 | 磷铂及其在治疗癌症中的用途 |
| US20130236568A1 (en) | 2011-01-12 | 2013-09-12 | Ohio University | Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof |
| EP2729526B1 (en) | 2011-07-08 | 2017-10-04 | Dow Global Technologies LLC | Polyethylene blend composition suitable for blown film, method of producing the same, and films made therefrom |
| JP6027619B2 (ja) | 2011-10-05 | 2016-11-16 | ラシンドラ・エヌ・ボーズ | ホスファプラチン系抗腫瘍剤の大規模調製のための効率的プロセス |
| WO2013052839A1 (en) | 2011-10-05 | 2013-04-11 | Bose Rathindra N | Efficient processes for large scale preparation of phosphaplatins antitumor agents |
| MX365635B (es) | 2011-10-20 | 2019-06-10 | Nerium Biotechnology Inc | Combinacion terapeutica para el tratamiento de cancer. |
| LT2855496T (lt) * | 2012-05-24 | 2017-04-10 | Phosplatin Therapeutics Llc | Fosfaplatinos junginių sintezės ir gryninimo būdai ir jų panaudojimas |
| EP2958568B1 (en) * | 2013-02-22 | 2020-03-04 | University Of Houston | Phosphaplatins as neuroprotective agents |
| WO2015127037A1 (en) * | 2014-02-19 | 2015-08-27 | University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
| MX370673B (es) | 2014-06-11 | 2019-12-19 | Univ Texas | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. |
| EP3397642A1 (en) | 2015-12-30 | 2018-11-07 | Atilim Universitesi | Dna targeted mono and heterodinuclear complexes |
| TWI791008B (zh) | 2017-01-06 | 2023-02-01 | 美商弗斯普萊汀治療股份有限公司 | 作為供骨癌或血癌治療用之治療劑的磷酸鉑(phosphaplatin)化合物 |
| JP7381083B2 (ja) | 2017-09-08 | 2023-11-15 | フォスプラティン テラピューティクス インコーポレイテッド | 免疫調節剤としてのホスファプラチン化合物およびその治療的使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291027A (en) | 1979-03-07 | 1981-09-22 | Engelhard Minerals & Chemicals Corp. | Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes |
| US4234500A (en) * | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes |
| CA2017739A1 (en) * | 1989-07-18 | 1991-01-18 | Engelhard Corporation | Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents |
| EP1644388A2 (en) * | 2003-06-27 | 2006-04-12 | ODANI, Akira | Bisphosphonate complexes |
| EP2177525A1 (en) * | 2007-07-06 | 2010-04-21 | TMRC Co., Ltd. | Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound |
| ES2495743T3 (es) * | 2007-08-06 | 2014-09-17 | Ohio University | Fosfaplatinos y su uso en el tratamiento de cánceres resistentes a cisplatino y carboplatino |
-
2008
- 2008-08-06 ES ES08797320.2T patent/ES2495743T3/es active Active
- 2008-08-06 WO PCT/US2008/072397 patent/WO2009021081A2/en not_active Ceased
- 2008-08-06 EP EP13182512.7A patent/EP2668949A1/en not_active Withdrawn
- 2008-08-06 JP JP2010520294A patent/JP5385274B2/ja active Active
- 2008-08-06 EP EP08797320.2A patent/EP2173337B1/en active Active
- 2008-08-06 WO PCT/US2008/072398 patent/WO2009021082A2/en not_active Ceased
- 2008-08-06 PT PT87973202T patent/PT2173337E/pt unknown
- 2008-08-06 SI SI200831280T patent/SI2173337T1/sl unknown
- 2008-08-06 CN CN2008801015774A patent/CN101801369B/zh active Active
- 2008-08-06 DK DK08797320.2T patent/DK2173337T3/da active
- 2008-08-06 HR HRP20140808AT patent/HRP20140808T1/hr unknown
- 2008-08-06 US US12/187,376 patent/US7700649B2/en active Active
- 2008-08-06 PL PL08797320T patent/PL2173337T3/pl unknown
-
2010
- 2010-03-11 US US12/722,189 patent/US8034964B2/en active Active
-
2011
- 2011-08-30 US US13/221,458 patent/US8445710B2/en active Active
-
2013
- 2013-03-15 US US13/842,885 patent/US8653132B2/en active Active
- 2013-06-07 JP JP2013120309A patent/JP5647300B2/ja active Active
-
2014
- 2014-08-27 CY CY20141100686T patent/CY1115504T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2173337T1 (sl) | 2014-10-30 |
| US8034964B2 (en) | 2011-10-11 |
| US20110313182A1 (en) | 2011-12-22 |
| WO2009021082A3 (en) | 2009-04-23 |
| US20090042838A1 (en) | 2009-02-12 |
| JP5385274B2 (ja) | 2014-01-08 |
| WO2009021081A3 (en) | 2009-05-07 |
| PL2173337T3 (pl) | 2014-11-28 |
| ES2495743T3 (es) | 2014-09-17 |
| WO2009021081A2 (en) | 2009-02-12 |
| HRP20140808T1 (hr) | 2014-10-24 |
| US20130237503A1 (en) | 2013-09-12 |
| CN101801369B (zh) | 2012-09-19 |
| HK1143551A1 (en) | 2011-01-07 |
| WO2009021082A2 (en) | 2009-02-12 |
| EP2173337A4 (en) | 2010-10-27 |
| EP2173337A2 (en) | 2010-04-14 |
| US20100233293A1 (en) | 2010-09-16 |
| JP2010535803A (ja) | 2010-11-25 |
| US7700649B2 (en) | 2010-04-20 |
| EP2668949A1 (en) | 2013-12-04 |
| EP2173337B1 (en) | 2014-07-30 |
| CN101801369A (zh) | 2010-08-11 |
| US8653132B2 (en) | 2014-02-18 |
| JP5647300B2 (ja) | 2014-12-24 |
| JP2013227218A (ja) | 2013-11-07 |
| US8445710B2 (en) | 2013-05-21 |
| PT2173337E (pt) | 2014-09-03 |
| DK2173337T3 (da) | 2014-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115504T1 (el) | Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινη | |
| Wani et al. | Recent advances in iron complexes as potential anticancer agents | |
| Hickey et al. | Mitochondria-targeted chemotherapeutics: the rational design of gold (I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols | |
| Li et al. | Half-sandwich iridium and ruthenium complexes: effective tracking in cells and anticancer studies | |
| Braga et al. | A new age for iron: antitumoral ferrocenes | |
| CY1122855T1 (el) | Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου | |
| Ban et al. | Boron‐based drug design | |
| Brabec | DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair | |
| Panchangam et al. | Antitumor effects of Ir (III)-2 H-indazole complexes for triple negative breast cancer | |
| EA201000994A3 (ru) | Химически модифицированные малые молекулы | |
| Mehmood et al. | Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibodies perspective | |
| CY1112052T1 (el) | Γονιδια και πολυπεπτιδια που σχετιζονται προς τους καρκινους ανθρωπινων κολον | |
| Pettinari et al. | From sunscreen to anticancer agent: Ruthenium (II) arene avobenzone complexes display potent anticancer activity | |
| Sahu et al. | LVVO-ethyl Maltol-based Metallodrugs (L2–= tridentate ONO ligands): hydrophobicity, hydrolytic stability, and cytotoxicity via ROS-mediated apoptosis | |
| Meng et al. | Synthesis and biological evaluation of substituted 3-(2′-benzimidazolyl) coumarin platinum (II) complexes as new telomerase inhibitors | |
| McGivern et al. | Innovative DNA-targeted metallo-prodrug strategy combining histone deacetylase inhibition with oxidative stress | |
| Nano et al. | Rhodium complexes targeting DNA mismatches as a basis for new therapeutics in cancers deficient in mismatch repair | |
| Clemente et al. | Platinacycles containing a primary amine platinum (II) compounds for treating cisplatin-resistant cancers by oxidant therapy | |
| Gao et al. | Synthesis, characterization, DNA binding, apoptosis and molecular docking of three Mn (II), Zn (II) and Cu (II) complexes with terpyridine‐based carboxylic acid | |
| Elie et al. | Auranofin-Based Analogues Are Effective Against Clear Cell Renal Carcinoma In Vivo and Display No Significant Systemic Toxicity | |
| Michlewska et al. | Ruthenium dendrimers against acute promyelocytic leukemia: In vitro studies on HL-60 cells | |
| Acuña et al. | Targets, mechanisms and cytotoxicity of half-sandwich Ir (III) complexes are modulated by structural modifications on the benzazole ancillary ligand | |
| Crlikova et al. | Antiproliferative activity and associated DNA interactions of [Co2L3] 6+ cylinders derived from bis (bidentate) 2-pyridyl-1, 2, 3-triazole ligands | |
| Klajner et al. | DNA binding to an anticancer organo-ruthenium complex | |
| Borah et al. | β-Cyclodextrin Encapsulated Platinum (II)-Based Nanoparticles: Photodynamic Therapy and Inhibition of the NF-κB Signaling Pathway in Glioblastoma |